Predictive Oncology Inc.

Predictive Oncology Inc., a knowledge-driven company, focuses on developing optimal cancer therapies using artificial intelligence (AI) in the United States. The company operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers AI-driven predictive models of tumor drug response to enhance clinical outcomes for patients; and patient-centric drug discovery using active learning asset technology. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.